Abstract: Provided are pharmaceutical carriers suitable based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by formulated for topical administration to the eye.

Abstract: Described herein are methods of forming hydrogels comprising combining (a) a water-soluble polymer comprising thiol groups, and (b) a water-soluble metal salt in an aqueous solution. The hydrogels form rapidly. Hydrogels and related methods, uses, and products also are described.

Abstract: The present invention relates to water soluble and completely absorbable and/or physiologically degradable hemostatic compositions having a wax or wax-like base effective for use in tamponade hemostasis of bone or cartilage.

Abstract: A liquid composition is provided. The composition includes at least one active pharmaceutical ingredient dissolved in a liquid carrier system. The liquid carrier includes polyethylene glycol and a co-solvent selected from the group consisting of: propylene glycol, glycerin, and a sugar alcohol. The composition is essentially dye tree, present as a single-phase at room temperature, and optionally contains water.

Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.

Abstract: A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution; (b) providing an excipient to at least one of the precipitant solution, the anti-solvent solution and the suspension of drug nanoparticles, the excipient being selected to maintain said drug nanoparticles in a dispersed state when in liquid form; and (c) drying the suspension of drug nanoparticles containing the excipient therein to remove solvent therefrom, wherein removal of the solvent causes the excipient to solidify and thereby form micro-sized matrix particles, each micro-sized particle being comprised of drug nanoparticles dispersed in a solid matrix of the excipient.

Abstract: A spray-chilled particulate delivery system that has a crystalline matrix structure and includes a volatile hydrophobic active ingredient and a carrier material of erythritol, mannitol and mixtures thereof 75% or more of the carrier material, relative to the total weight of the carrier material, is in crystalline form. The system is prepared by a process that includes the steps of forming a melt of the carrier material, incorporating a volatile hydrophobic active ingredient into the melt, forming a melt-mixture comprising an emulsion, dispersion or suspension of the volatile hydrophobic active ingredient in the melt, forming discrete particles of the melt mixture, and cooling the discrete particles.

Abstract: A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.

Abstract: The present invention is a natural, cell-free tissue replacement that does not require difficult or extensive preparation made by washing tissue replacement in a solution including one or more sulfobetaines and an anionic surface-active detergent and washing the tissue replacement in serial solutions of the buffered salt to remove excess detergent. The natural, cell-free tissue replacement may be a nerve graft that supports axonal regeneration, guides the axons toward the distal nerve end and/or is immunologically tolerated. Other forms of the invention are a composition and kit prepared by the method of making a native, cell-free tissue replacement. The present invention may be modified for use in diagnostic, therapeutic, and prophylactic applications.

Abstract: An immuno-compatible hydrogel system is provided that is resistant to protein binding. The hydrogel system is prepared by contacting a hydrogel solution with a cross-linking agent to form a gel, exposing the gel to an aqueous solution comprising a first polyelectrolyte to form a polyelectrolyte-coated hydrogel, exposing the polyelectrolyte-coated hydrogel to a second polyelectrolyte to form a crosslinked matrix and exposing the matrix to conditions which eliminates, or at least reduces, protein binding sites on the matrix.

Abstract: The present invention provides an oil-in-water emulsion cosmetic that is excellent in the resilient and supple (in other words, firm, tensional, and elastic) feel and also excellent in the softness and moisturizing effect. The oil-in-water emulsion cosmetic of the present invention is characterized by comprising the following components: (A) 0.1 to 5 mass % of hydrogenated polyisobutene with a number average molecular weight of 2000 to 3000, (B) 0.1 to less than 1 mass % of higher alcohol, (C) 1 to 25 mass % of an oil component, (D) 0.3 to 5 mass % of surfactant, (E) 0.05 to 5 mass % of water-soluble thickener, and (F) an aqueous component, wherein the blending quantity of nonpolar oil is 30% or lower of the total amount of component (C).

Abstract: The present invention relates to a liquid formulation containing at least one carotenoid, at least one hydrophilic protective colloid and at least one water-miscible alcohol. The formulation according to the invention can be added directly to aqueous or non-aqueous preparations. The invention compositions can be used in animal feed, human food or a dietary supplement and in pharmaceutical and cosmetic preparations.

Abstract: The invention relates to a method of use of certain derivatives of formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein R1 represents a hydrogen atom, a C1-4 alkyl or alkenyl group, or a (CHR)2OH group, each R being a hydrogen atom or a methyl group; R2 represents a hydrogen atom or a methyl, ethyl or n-propyl group; and R3 represents a hydrogen atom or a methyl group, as perfuming ingredients. The present invention concerns also certain compounds and compositions or articles containing such compounds.

Abstract: Methods of ex situ synthesis of graphene, graphene oxide, reduced graphene oxide, other graphene derivative structures and nanoparticles useful as polishing agents are disclosed. Compositions and methods for polishing, hardening, protecting, adding longevity to, and lubricating moving and stationary parts in devices and systems, including, but not limited to, engines, turbos, turbines, tracks, races, wheels, bearings, gear systems, armor, heat shields, and other physical and mechanical systems employing machined interacting hard surfaces through the use of nano-polishing agents formed in situ from lubricating compositions and, in some cases, ex situ and their various uses are also disclosed.

Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.

Abstract: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.

Abstract: The following invention relates to a taste enhancer and a method of enhancing taste. The invention relates the use of a cooling enhancing composition which provides cooling enhancement when combined with other cooling compounds.

Abstract: The invention relates to a compound of general formula I represented below: wherein: R1, R2 and R3 each independently represent a hydrogen atom or saturated or unsaturated, branched or non-branched C1 to C5 alkyl group; m is an integer between 1 and 4; n is an integer between 2 and 4; characterised in that the ring is saturated and comprises from 5 to 8 carbons, that the total number of carbons of the ring and of the radicals R1, R2 and R3 is between 7 and 11 and it being understood that said compound of formula (I) is not: 6-cycloheptylidenehexanal 4-(4-methylcyclohexylidene)-butanal 4-(4-tert-butylcyclohexylidene)-butanal 4-(3,3,5-trimethylcyclohexylidene)-butanal as well as a method of synthesising said compounds, and their uses in perfumery.

Abstract: The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.

Abstract: The invention provides a method for the preparation of a carrier liquid which comprises the steps of: (I) preparing a single phase solution comprising: (a) a solvent or a mixture of miscible solvents, (b) a liquid carrier material, which is soluble in solvent (a), and (c) a dopant material which is also soluble in solvent (a); (II) cooling (preferably freezing) the single phase solution produced in step (I) to a temperature at which at least both the solvent (a) and carrier material (b) become solid; and (III) removing solid solvent (a) from the cooled (frozen) single phase solution in vapour form, such that the remaining cooled (frozen) carrier material (b) and dopant material (c) are returned to ambient temperature thus providing a product of liquid carrier material (b) having dopant material (c) dispersed therein.

Abstract: Branched organopolysiloxanes of low molecular weight contain bonded arylalkyl groups. Si—C bonded surfactant groups, preferably polyoxyalkylene polyether groups, and long chain alkyl groups, exhibit a high refractive index, are completely or partially self-emulsifying, and are compatible with a variety of cosmetically acceptable oils and solvents.

Abstract: The present invention provides a formulation comprising a pesticide and/or a plant growth regulator; an acyl morpholine of the formula (I) where R is H, CH3 or C2H5; and a polar aprotic co-solvent different from an acyl morpholine of formula (I). The formulation can be used in treatment of plants, and is especially well suited for use as a soluble liquid formulation.

Abstract: The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.

Abstract: The invention relates to a method for preparing a stable oil-in-water emulsion without adding an emulsifier. According to the method, a mixture of a lipid phase and an aqueous phase is subjected to vibrating energy, in a sealed container, by applying a transducer operating at a frequency of more than 900 kHz.

Abstract: Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick “highs”. The formulations assist the smoker to become dissatisfied with smoking, until he or she willingly gives up the habit or at least cuts down on the number of cigarettes smoked per day as an initial step towards quitting in the future. The formulations can also be used in conjunction with other known formulations, such as nicotine gum or patch. The formulations contain hydrophilic polymers, for example, polyethylene glycol (PEG) alone or in combination or polyvinyl pyrrolidone (PVP) (also known as povidone or polyvidone alone or in combination.), sweeteners and/or flavorings, viscosity modifiers/binders, and pH or buffering agents.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: The invention relates to the field of depositing agents on surfaces using highly volatile silicone solvents. Particularly, the invention relates to novel compositions useful for depositing agents on skin and other surfaces.

Abstract: The present invention relates to a liquid crystal compound that can be used as a base for injection formulations. The present invention provides an amphipathic compound having the following general formula (I): wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group generated by removal of one hydroxyl group from any one selected from the group consisting of glycerol, erythritol, pentaerythritol, diglycerol, triglycerol, xylose, sorbitol, ascorbic acid, glucose, galactose, mannose, dipentaerythritol, maltose, mannitol, and xylitol; as well as a base for injection formulations and depot formulation comprising the same.

Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.

Abstract: The present invention relates to a liquid organopolysiloxane having fluidity at a temperature of at least 100° C., having a silicon-bonded sugar alcohol-modified group, and having a crosslinked structure comprising a carbon-silicon bond in the crosslinking portion. The liquid organopolysiloxane of the present invention has excellent emulsion characteristics, imparts excellent tactile sensation, and, in particular, when compounded in an external use preparation or a cosmetic composition containing water and oil, takes advantage of the effects of water to suppress oiliness and provide a smooth, thick feeling when applied, a natural feeling to the skin with good compatibility with the skin, excellent moisturizing effects, and an excellent sensation during use without any oily stickiness.

Abstract: The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active agents for the treatment of human skin, especially in the treatment of acne, acne related symptoms, a tetracycline antibiotic responsive acne related disorder, skin disorder caused by a bacteria, and a tetracycline antibiotic responsive sebaceous gland disease, P. acne bacteria associated disorders, and other superficial infections, including skin infections.

Abstract: Disclosed is an adjuvant for improving the bioavailability of bioactive compositions. The adjuvant is prepared from a byproduct of mint flavor production. In vitro and in vivo testing confirms effectiveness. The adjuvant contains a mixture of compounds which is effective to improve the oral bioavailability of a bioactive composition normally having limited absorptivity, and it comprises a mixture of nonpolar compounds and compounds with some polar characteristics. In preferred form the nonpolar compounds comprise compounds selected from a group that includes terpene hydrocarbons and terpene derivatives and the compounds with some polar characteristics comprise compounds selected from a group that includes aldehydes, alcohols and ketones. The preferred compositions will have a ratio of nonpolar compounds and compounds with some polar characteristics is within the range of from 5:1 to 20:1. The adjuvants can enhance delivery of CoQ10 and other bioactive compositions, such as carotenoids (e.g.

Abstract: The invention provides an oil-in-water type cosmetic emulsion which can be applied to the skin without stickiness, and impart resilient and supple feel to the skin, while having good stability without causing viscosity decrease or separation even during a long-term storage. The oil-in-water type cosmetic emulsion comprises (a) a higher alcohol having 14 to 22 carbon atoms, (b) a hydrophilic polyoxyethylene alkyl ether, and (c) a glycerin monoalkyl ether, wherein alkyl moieties in (b) and (c) are linear saturated alkyl chains, and molar concentrations of (a) to (c) satisfy a relation [(b)+(c)]/(a)=0.1 to 1.0, and preferably satisfy a relation [(a)+(c)]/(b)=3 to 20.

Abstract: Drug substances comprising a amine containing pharmaceutically active compound, and at least one of an alditol acetal and an aromatic organic acid as an addition salt or an additive.

Abstract: In the present invention, a method of producing stable bare colloidal gold nanoparticles is disclosed. The nanoparticles can subsequently be subjected to partial or full surface modification. The method comprises preparation of colloidal gold nanoparticles in a liquid by employing a top-down nanofabrication method using bulk gold as a source material. The surface modification of these nanoparticles is carried out by adding one or multiple types of ligands each containing functional groups which exhibit affinity for gold nanoparticle surfaces to produce the conjugates. Because of the high efficiency and excellent stability of the nanoparticles produced by this method, the fabricated gold nanoparticle conjugates can have surface coverage with functional ligands which can be tuned to be any percent value between 0 and 100%.

Abstract: The present invention relates to processes for the preparation of compounds of the formula (Ia) by reacting styrene with a secondary alkanol and the hydrogenation of the resulting phenyl-substituted tertiary alkanol. In addition, the invention relates to compounds of the formula (Ia) and to the use of such compounds as fragrances, and also to compositions which comprise compounds of the formulae (Ia) and (Ib).

Abstract: The present invention is directed to a stable fluorocarbon emulsion having a continuous aqueous phase and discontinuous fluorocarbon phase comprising two fluorocarbons and surprisingly demonstrates that perfluorodecyl bromide is as effective in stabilizing perfluorooctyl bromide emulsions of certain concentrations than much more highly concentrated perfluorooctyl bromide/perfluorodecyl bromide emulsions without the significant problems experienced in higher concentrated emulsions such as longer organ retention times, formation of PFDB crystals, larger emulsion particles, manufacturing problems and inability of repeat dosing inherent with higher concentrations of perfluorodecyl bromide.

Abstract: Provided are azeotropic and azeotrope-like compositions of trans-1,3,3,3-tetrafluoropropene (HFO-1234ze(E)) and water. Such azeotropic and azeotrope-like compositions are useful in isolating trans-1,3,3,3-tetrafluoropropene from impurities during production. Azeotropes of the instant invention are similarly useful in final compositions or for the manufacture of final compositions, such as blowing agent, propellants, refrigerants, diluents for gaseous sterilization and the like.

Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.

Abstract: An improved monolithic drug delivery dosage form releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relaxes on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate.

Abstract: A water-in-silicone oil macroemulsion cosmetic composition of waterdrop quick break type is provided. The silicone oil phase part contains a partly crosslinked emulsifiable silicone elastomer, a partly crosslinked non-emulsifiable silicone elastomer, and silicone oil, and the aqueous phase part contains glycerin as a freeze stabilizer and at least one member selected from polyols and lower alcohols and/or at least one member selected from organic acid salts and inorganic salts as a mixture of freeze stabilizers. The cosmetic composition instantaneously releases water upon application on the skin. The cosmetic composition is stable at the extremely low temperature of ?20° C., and it retains its dispersion stability even after repeated freezing and thawing, and accordingly, and it can be used in a variety of cosmetic product.

Abstract: The present disclosure relates to cosmetic compositions comprising an organosilane (A) having the formula: (R1)n(R2O)(3?n)SiR3O(CH2CH2O)a(C3H6O)bR4 where n is 1, 2, or 3, a?1, b may vary from 0 to 30, with the proviso a?b, R1 is a hydrocarbon group containing 1 to 12 carbon atoms, R2 is hydrogen or an alkyl group containing 1 to 6 carbon atoms, R3 is a divalent hydrocarbon group containing 2 to 12 carbon atoms, R4 is hydrogen, R1, or an acetyl group; and a cosmetic ingredient (B), and optionally in a cosmetically acceptable medium.

Abstract: Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anti cancer-associated fibroblast composition; and a method for treatment of cancer.

Abstract: Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.

Abstract: A process for reducing the intensity of the intrinsic bitter taste of a water soluble active which comprises dry mixing of said active with ?-cyclodextrin.

Abstract: Alkyl ether sulfates having 1 to 9 carbon atoms in the alkyl chain and 1 to 20 alkyleneoxy units in the ether moiety are suitable for use as low-foam additives for enhancing the activity of water-soluble or partially water-soluble agrochemicals. They can be used to produce low-foam preparations for crop protection.

Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including krill oil in an oil-in-water emulsion. A parenterally applicable pharmaceutical composition, including an oil-in-water emulsion including a phospholipid obtained from a marine crustacean.

Abstract: A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure.

Abstract: Provided is an adhesion preventing medical material including a bioresorbable base material and a polyhydric alcohol or aqueous polyhydric alcohol solution, which contains the polyhydric alcohol, held in the bioresorbable base material. The bioresorbable base material includes a bioresorbable material, and has a swelling degree of 200 to 3,000 mass % and a water elution rate of not higher than 10 mass %. After immersed for 3 hours in water of 25° C. in an amount at least 50 times a total mass of the aqueous polyhydric alcohol solution or aqueous polyhydric alcohol solution and the bioresorbable base material, the polyhydric alcohol remains in an amount of not greater than 30 mass % of that of the polyhydric alcohol before the immersion.

Abstract: A branched polyamine comprises about 45 to about 70 backbone tertiary amine groups, about 90 to about 140 backbone secondary amine groups, a positive number n? greater than 0 of backbone terminating primary amine groups, and a positive number q greater than 0 of backbone terminating carbamate groups of formula (2): wherein (n?+q) is a number equal to about 45 to about 70, the starred bond of formula (2) is linked to a backbone nitrogen of the branched polyamine, L? is a divalent radical comprising 3 to 30 carbons, and q/(n?+q)×100% equals about 9% to about 47%.